9,11-Dehydro-beta-boswellic acidCAS# 471-65-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 471-65-8 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C30H46O3 | M.Wt | 454.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
9,11-Dehydro-beta-boswellic acid Dilution Calculator
9,11-Dehydro-beta-boswellic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1993 mL | 10.9963 mL | 21.9925 mL | 43.985 mL | 54.9813 mL |
| 5 mM | 0.4399 mL | 2.1993 mL | 4.3985 mL | 8.797 mL | 10.9963 mL |
| 10 mM | 0.2199 mL | 1.0996 mL | 2.1993 mL | 4.3985 mL | 5.4981 mL |
| 50 mM | 0.044 mL | 0.2199 mL | 0.4399 mL | 0.8797 mL | 1.0996 mL |
| 100 mM | 0.022 mL | 0.11 mL | 0.2199 mL | 0.4399 mL | 0.5498 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isocucurbitacin D
Catalog No.:BCN0206
CAS No.:68422-20-8
- Cuscutamine
Catalog No.:BCN0205
CAS No.:122170-93-8
- Batatasin IV
Catalog No.:BCN0204
CAS No.:60347-67-3
- Euphorbia factor L24
Catalog No.:BCN0203
CAS No.:1613700-13-2
- Notoginsenoside L13
Catalog No.:BCN0202
CAS No.:2485859-56-9
- Physalin X
Catalog No.:BCN0201
CAS No.:72497-31-5
- Arvenin III
Catalog No.:BCN0200
CAS No.:65597-45-7
- Parishin G
Catalog No.:BCN0199
CAS No.:952283-93-1
- alpha-Costic acid
Catalog No.:BCN0198
CAS No.:28399-17-9
- Batatasin V
Catalog No.:BCN0197
CAS No.:65817-45-0
- Menisperine
Catalog No.:BCN0196
CAS No.:25342-82-9
- 8'-O-(3-hydroxy-3-methylglutaryl)-8'-hydroxyabscisic acid
Catalog No.:BCN0195
CAS No.:69790-31-4
- (3beta,22alpha)-26-(beta-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl 2-O-(6-deoxy-alpha-mannopyranosyl)-beta-glucopyranosiduronic acid
Catalog No.:BCN0208
CAS No.:107783-53-9
- Isophysalin G
Catalog No.:BCN0209
CAS No.:152221-21-1
- Lathyranoic acid A
Catalog No.:BCN0210
CAS No.:850560-44-0
- 4',5-Di-O-methyl quercetin
Catalog No.:BCN0211
CAS No.:100648-56-4
- 7-Ketocholesterol
Catalog No.:BCN0212
CAS No.:566-28-9
- 3-Oxo-olean-12-en-28-oic acid methyl ester
Catalog No.:BCN0213
CAS No.:1721-58-0
- Physalin F
Catalog No.:BCN0214
CAS No.:57423-71-9
- 4-Methyl-6-phenyl-2H-pyranone
Catalog No.:BCN0215
CAS No.:4467-30-5
- Rutarensin
Catalog No.:BCN0216
CAS No.:119179-04-3
- 3,5,6,7,8,4'-hexamethoxyflavone
Catalog No.:BCN0217
CAS No.:34170-18-8
- 3',5-Di-O-methyl quercetin
Catalog No.:BCN0218
CAS No.:40554-94-7
- Coryneine
Catalog No.:BCN0219
CAS No.:7224-66-0
Urease inhibitory activities of beta-boswellic acid derivatives.[Pubmed:23351363]
Daru. 2013 Jan 2;21(1):2.
UNLABELLED: BACKGROUND AND THE PURPOSE OF THE STUDY: Boswellia carterii have been used in traditional medicine for many years for management different gastrointestinal disorders. In this study, we wish to report urease inhibitory activity of four isolated compound of boswellic acid derivative. METHODS: 4 pentacyclic triterpenoid acids were isolated from Boswellia carterii and identified by NMR and Mass spectroscopic analysis (compounds 1, 3-O-acetyl-9,11-Dehydro-beta-boswellic acid; 2, 3-O-acetyl-11-hydroxy-beta-boswellic acid; 3. 3-O- acetyl-11-keto-beta-boswellic acid and 4, 11-keto-beta-boswellic acid. Their inhibitory activity on Jack bean urease were evaluated. Docking and pharmacophore analysis using AutoDock 4.2 and Ligandscout 3.03 programs were also performed to explain possible mechanism of interaction between isolated compounds and urease enzyme. RESULTS: It was found that compound 1 has the strongest inhibitory activity against Jack bean urease (IC50 = 6.27 +/- 0.03 muM), compared with thiourea as a standard inhibitor (IC50 = 21.1 +/- 0.3 muM). CONCLUSION: The inhibition potency is probably due to the formation of appropriate hydrogen bonds and hydrophobic interactions between the investigated compounds and urease enzyme active site and confirms its traditional usage.
Two new triterpenoids from the resin of Boswellia carterii.[Pubmed:21409679]
J Asian Nat Prod Res. 2011 Mar;13(3):193-7.
Two new triterpenoids, 3-oxotirucalla-7,9(11),24-trien-21-oic acid (1) and 18Halpha,3beta,20beta-ursanediol (2), along with 15 known triterpenes, alpha-amyrin, alpha-boswellic acid, beta-boswellic acid, acetyl alpha-boswellic acid, acetyl beta-boswellic acid, 9,11-Dehydro-beta-boswellic acid, 9,11-dehydro-alpha-boswellic acid, acetyl 11alpha-methoxy-beta-boswellic acid, 11-keto-beta-boswellic acid, acetyl 11-keto-beta-boswellic acid, acetyl alpha-elemolic acid, 3beta-hydroxytirucalla-8,24-dien-21-oic acid, elemonic acid, 3alpha-hydroxytirucalla-7,24-dien-21-oic acid, and 3alpha-hydroxytirucall-24-en-21-oic acid, were isolated from the resin of Boswellia carterii Birdw.
Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues.[Pubmed:10978197]
J Nat Prod. 2000 Aug;63(8):1058-61.
Pentacyclic triterpenes from the 11-keto-boswellic acid series were identified as the active principal ingredients of Boswellia resin, inhibiting the key enzyme of leukotriene biosynthesis, 5-lipoxygenase (5-LO). Of the genuine boswellic acids hitherto characterized, 3-O-acetyl-11-keto-beta-boswellic acid, AKBA (1), proved to be the most potent inhibitor of 5-LO. In the course of purification of further boswellic acid derivatives from Boswellia resin, we observed the degradation of the natural compound 3-O-acetyl-11-hydroxy-beta-boswellic acid (2) to the thermodynamically more stable product 3-O-acetyl-9, 11-dehydro-beta-boswellic acid (4). The metastable intermediate of this conversion, under moderate conditions of workup in methanolic solutions, was identified as 3-O-acetyl-11-methoxy-beta-boswellic acid (3). The novel artifactual boswellic acid derivatives inhibited 5-LO product formation in intact cells with different characteristics: 4 almost totally abolished 5-LO activity, with an IC(50) of 0.75 microM, whereas 3 and 9,11-Dehydro-beta-boswellic acid (5), the deacetylated analogue of 4, were incomplete inhibitors. The data suggest that the conditions chosen for the workup of Boswellia extracts could significantly influence the potency of their biological actions and their potential therapeutic effectiveness.
